#ESMO26 DeLLphi-305: tarlatamab+durva 对比 durva，一线维持治疗 ES-SCLC
➡️ OS 21.1 对比 12.7 月，HR 0.42
➡️ PFS 7.4 对比 1.9 月，HR 0.34
➡️ CRS 49.6%（G3+ 0.4%）
很荣幸能参与这项改变实践的研究，担任全球指导委员会成员！！
@LungCancerRx @OncoAlert @oncodaily
256 浏览 · 7 赞 · 4 转发 · 1 回复
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- Ashray Maniar@ManiarAshray
@ADesaiMD @LungCancerRx @OncoAlert @oncodaily @sands_jacob @drshieldsmd @AnaVManana @DevikaDasMD @GlopesMd @RManochakian @FawziAbuRous @lungoncdoc @LaurenByersMD @SuyogCancer Great OS results, excited to see and hopefully propels more outpt tarlatamab protocols. I assume that the PFS and ORR are based on the first maintenance cycle instead of initiation of therapy?
来源：Aakash Desai · x.com